Recent years have seen critics examine the "one-sizefits-all" concept in public health. Nevertheless, it is the basis for the World Health Organization "Guideline: Vitamin A supplementation in infants and children 6-59 months of age" [1] (see box 1). In the same conversation, we use the terms disparity and equity. Disparity, derived from not on a par, is a synonym for inequality. Equity connotes equal treatment or situation. In a positive sense, it signifies equality of condition within an optimal state of well-being, as an aspirational ideal. However, one could imagine having an alternative equity, that is, one with everyone at the same level, but near the bottom rung of the ladder. Generally, what we confront in a baseline public health assessment, however, are severe disparities of various kinds.
Such was the case in Aceh, Indonesia, in the 1980s, where Sommer et al. [2] associated vitamin A deficiency with excess mortality in a population of children; only 4.9% actually had night blindness and/ or Bitot's spots as overt clinical manifestations of hypovitaminosis A. As a follow-up response, in a cluster-randomized intervention trial, the Aceh Group supplemented children with a periodic oral dose of 200,000 IU of retinyl palmitate to address vitamin A deficits across the whole preschool sample, without differentiating which children might have needed it more than others [3] . When the dramatic effect of a 34% reduction in mortality attributable to the intervention was found, the format of the experiment, i.e., universal periodic vitamin A supplementation, became inscribed in public health policy and programs. This was the genesis of a one-size-fits-all talisman. It was a solution based on equity of exposure across the population, but for a situation that is inherently rooted in a wide disparity of individual vitamin A status and risk of deficiency.
The article in this issue of the Food and Nutrition Bulletin by Rah et al. [4] describes the uneven application of the mandate for vitamin A supplementation among children 6 to 59 months of age across 15 states in India. It finds two states, Bihar and Odisha, to have the highest coverage rates. It further examines the putative factors and local characteristics contributing to the successful distribution in these two jurisdictions, and offers them as lessons to extend to the rest of the nation. Seeking 100% supplementation coverage is lauded as the goal by the authors [4] .
The discipline of health economics, however, points out a basic principle: If covering all individuals has a fixed cost, as the number of individuals at risk for a given adverse outcome (such as death) decreases, the cost to prevent that outcome increases in a steep and reciprocal manner. Public health officials are then faced with the morally troubling question: How much can we invest in preventing the last few deaths? The options are either to find a less expensive universal coverage approach or to implement a case-finding solution with a lower overall cost.
Periodic supplementation with vitamin A has been and continues to be a child-survival measure that reduces deaths from childhood infections in a situation of background vitamin A deficiency in a population. It is, however, not a sustainable solution for the Editorial Will universal periodic vitamin A supplementation ever reach retirement age? BOX 1. WHO guidelines for vitamin A supplementation in 6-to 59-month-old children Vitamin A supplementation is recommended for infants and young children 6-59 months of age in areas where vitamin A deficiency is considered a public health problem (i.e., where the prevalence of night blindness in children 24-59 months of age is ≥ 1% or where the prevalence of vitamin A deficiency [serum retinol ≤ 0.7 μmol/L] is ≥ 20% in infants and young children 6-59 months of age). High-quality evidence indicates that vitamin A supplementation reduces all-cause mortality among children in this age range who reside in these settings. The suggested dosing schedule for infants 6-11 months of age is 100,000 IU vitamin A (provided as oil-based retinyl palmitate or retinyl acetate) on one occasion and 200,000 IU vitamin A every 4-6 months for children 12-59 months of age. Source: World Health Organization [1] underlying vitamin A deficiency in individuals. In fact, based on both theoretical modeling [5] and empirical observation [6] , standard periodic administration of high-dose vitamin A is not sufficient to reverse hypovitaminosis A for an entire 6-month period. Thus, supplementation can be likened to extracorporeal dialysis in the treatment of end-stage renal failure; it prevents death by repeated applications of rescue therapy, but it does not cure the underlying condition.
Insofar as periodic vitamin A supplementation is a child-survival measure in the face of vitamin A deficiency, there would logically be two situations in which it would become no longer applicable or appropriate. The former is in a setting of persistently high mortality rates among children under 5 years of age, but in the absence of any background of vitamin A deficiency. One must be certain that hypovitaminosis A is still holoendemic to justify continued barking up the supplementation tree. The other situation is when underlying child mortality rates have fallen to such low values-even with documented vitamin A deficiency-that there is virtually no mortality left to prevent through public health measures. One format toward moving forward is to cast off both possibilities as unlikely and not worthy of investigation and to proceed with the status quo. The other is to break the mold, undertake the effort to evaluate for such possibilities, and make the necessary innovative adjustments in program strategies and tactics based on the findings.
Since the effects of periodic supplementation on vitamin A status are admittedly transient [5, 6] , a third way would be to support the development of public health measures with a more durable effect on improving vitamin A status, thus eliminating the fundamental threshold condition for supplementation. It has not gone without commentary that two of the studies used to justify periodic supplementation did not use the megadose of the vitamin across wide intervals, but a rather steady administration. Muhilal et al. [7] in Indonesia conducted an intervention with vitamin A-fortified monosodium glutamate for 11 months in children aged 0 to 5 years and observed a 44% reduction in mortality from the previous year. Rahmathullah et al. [8] provided 8,333 IU of vitamin A weekly to preschool children in a randomized community trial in southern India over 12 months and confirmed a 54% reduction in mortality compared with a control group. The Indonesian [7] and south Indian [8] contributions, therefore, stand out from the remainder of early trial series, which were otherwise all based on high-dose supplements, in their relatively low vitamin A dosage and continuous or frequent consumption [9] . Thus, they seem to replicate the exposure effects obtained with vitamin "fortification". This feature perhaps explains why the reductions in mortality at these two sites were both over twice the 22% decrease of the pooled effect-size in the historical systematic review by Beaton and colleagues [9] . Programmatic elimination of vitamin A deficiency, therefore, can be likened to kidney transplantation in renal failure, as it provides a self-sustainable, long-term solution. As the medical technology for kidney transplantation has improved, the nephrology community has clearly embraced it over the various modes of intermittent dialysis.
At some point, even for a country with as many annual under-five deaths as India, one might break with taboo and think outside of the (capsules) box-or in this case, the syrup bottle. That would mean asking the alternative question of whether a cumbersome and expensive measure like universal periodic supplementation can some day be retired. The model of Rah et al. [4] in their present article, in fact, is an ideal template, i.e., that of a differentiated, state-by-state inquiry. Rather than focusing on the local willpower and wherewithal to maximize the coverage of the supplementation, however, it would reexamine the nature of the disparities in vitamin A status and persisting mortality patterns. It would also evaluate the possibilities for implementation of more sustainable food-based or fortification measures. The nephrology community has accepted that transplantation provides a superior solution to intermittent dialysis for end-stage renal disease. The public health nutrition community will similarly conclude that, in theory, sustainable consumption of vitamin A from the diet is superior to periodic supplementation. Thus, while we improve the one-size-fits-all legacy of supplementation where the prevailing conditions justify its continued contribution to child survival, we need simultaneously to open a second front: This would represent one that focuses on reducing disparity in vitamin A status toward an equity-of-adequacy using creative local solutions of all sizes, shapes, and flavors. It would directly confront the nutritional and dietary conditions that are the basis for the current need to rely on 6-monthly syrup distribution to optimize survival in Indian communities.
